Noom Offers Cheaper Ozempic Alternative

Digital health company Noom has announced a new weight loss program featuring compounded semaglutide, the active ingredient in Novo Nordisk's popular weight loss and diabetes drug Ozempic. This program, called Noom GLP-1 RX, offers a cheaper alternative to branded medications, starting at $149.

• Noom has been providing weight loss programs for years and allows users to access branded medications through its platform.
• Noom joins other digital health companies like Hims & Hers and Sesame in offering compounded versions of GLP-1 medications to meet the growing demand for weight loss and diabetes drugs.

Compounded Ozempic: A Cheaper Option

The compounded semaglutide offered by Noom is a custom-made alternative to the brand-name Ozempic. It provides a cost-effective option for patients seeking weight loss or diabetes management, particularly when branded treatments face shortages.

• Branded Ozempic and Wegovy, another GLP-1 medication, cost approximately $1,000 per month before insurance.
• While insurance coverage for GLP-1s is prevalent for diabetes treatment, coverage for weight loss use is less common.
• Compounded medications are generally significantly cheaper than their branded counterparts, making them an attractive option for cost-conscious patients.

Noom GLP-1 RX Program Details

Noom's program offers a tiered pricing structure: $149 for the first month and $279 for subsequent months as the medication dosage increases. This program includes comprehensive support, encompassing:

• Intake form review by an obesity-trained doctor to determine medication suitability.
• Delivery of medications within a week.
• Injection training for patients.
• One-on-one communication with a coach and a Noom clinician.
• Psychology-based programs and tools, including protein intake tracking and resistance training features.
• A tapering option for patients who wish to discontinue medication use.
• A guarantee of a free year of Noom or significant medication discounts if weight is regained within 18 months after completing the program.

Ozempic & Weight Loss: A Growing Trend

Ozempic, along with Wegovy, has gained immense popularity as a weight loss medication. This demand has led to shortages and a rise in the exploration of alternative options, including compounded medications.

• GLP-1s like Ozempic mimic gut hormones to suppress appetite and regulate blood sugar levels, leading to significant weight loss in patients.
• The increasing availability of compounded GLP-1 medications is a response to the growing demand and challenges in accessing branded medications.
• Digital health companies are actively participating in this trend, offering compounded medications alongside their existing services to provide more affordable options to a wider patient base.

Concerns & Future Implications

While compounded medications provide a more affordable alternative, some concerns persist regarding their safety and efficacy. The FDA does not review the safety and efficacy of compounded products.

• The FDA recommends using approved branded GLP-1 medications when available, but it inspects certain compounding facilities that adhere to 503B regulations.
• Noom emphasizes its partnership with an FDA-regulated compounding pharmacy to ensure quality and safety standards.
• The increasing availability of compounded medications raises questions about their long-term effectiveness and potential side effects.
• The long-term use of GLP-1 medications and the potential for weight regain after discontinuing them are areas of ongoing research and debate.

Ozempic & the Future of Weight Loss

The growing popularity of Ozempic and other GLP-1 medications, coupled with the emergence of compounded alternatives, is reshaping the landscape of weight loss solutions. As more individuals seek effective weight management options, digital health companies are playing a crucial role in providing accessible and affordable solutions.

• Compounded medications offer a potentially cost-effective option, but their long-term efficacy and safety remain subject to ongoing evaluation.
• The future of weight loss will likely involve a combination of medication, lifestyle modifications, and personalized approaches to address individual needs and preferences.
• Digital health platforms have the potential to play a significant role in supporting patients on their weight loss journeys by providing access to medications, coaching, and personalized tools.